Yalelaan 60    VIA EDGAR
3584 CM Utrecht   
The Netherlands   

March 22, 2021

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549



Ms. Christie Wong


Mr. Al Pavot


Mr. Chris Edwards


Mr. Tim Buchmiller



LAVA Therapeutics B.V.


Registration Statement on Form F-1


File No. 333-253795



Acceleration Request


        Requested Date:         March 24, 2021


        Requested Time:        4:00 P.M. Eastern Time

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form F-1 to become effective on March 24, 2021, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable, or at such later time as its counsel may orally request via telephone call to the staff. The Registrant hereby authorizes each of Divakar Gupta, Christian Plaza and Josh Kaufman of Cooley LLP, counsel to the Registrant, to make such request on its behalf.

Once the Registration Statement has been declared effective, please orally confirm that event with Divakar Gupta of Cooley LLP at +1 212 479 6474, Christian Plaza at + 1 703 456 8006 or Josh Kaufman at +1 212 479 6495. Thank you for your assistance with this matter.

[Signature Page Follows]


/s/ Stephen Hurly

  Name: Stephen Hurly.
  Title:   Chief Executive Officer



Edward Smith, Chief Financial Officer, LAVA Therapeutics B.V.


Divakar Gupta, Cooley LLP


Christian Plaza, Cooley LLP


Josh Kaufman, Cooley LLP